Open access
Sep 2026
Next-gen glycoengineering: combining cellular and metabolic engineering to fine-tune mAb β1,4-galactosylation
N-linked Fc galactosylation drives variability in therapeutic mAb quality, affecting complement-dependent cytotoxicity and ADCC. Current control strategies suffer from narrow ranges, productivity loss, or unwanted glycoforms. Here, we combine metabolic and cellular glycoengineering by feeding 2-deoxy-2-fluorogalactose...
Apostolos Tsopanoglou, Mina Ghahremanzamaneh, Itzcóatl Gómez Aquino et al.
· bioRxiv · 0 citations